| sess_gap-methodol-20 | Methodology challenge: dataset 'SEA-AD Differential Expression: AD vs Control (M | 0.50 | 0 | 2 | scheduled | 2026-04-27 | |
| sess_gap-methodol-20 | Methodology challenge: dataset 'Allen Brain SEA-AD MTG 10x snRNA-seq' — evaluate | 0.50 | 0 | 2 | scheduled | 2026-04-27 | |
| fea-27014558ee0c | Does this figure provide adequate evidence for the claim 'Microglial-Amyloid-Cyt | 0.30 | 0 | 3 | completed | 2026-04-27 | |
| sess_hypdeb_h_4bb7fd | Hypothesis debate: Nutrient-Sensing Epigenetic Circuit Reactivation | 0.46 | 1 | 4 | completed | 2026-04-27 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| fea-6a076c941f7f | Does this figure provide adequate evidence for the claim 'Microglial-Amyloid-Cyt | 0.30 | 0 | 3 | completed | 2026-04-27 | |
| sess_hypdeb_h_var_55 | Hypothesis debate: Closed-loop focused ultrasound targeting EC-II SST interneuro | 0.54 | 1 | 4 | completed | 2026-04-27 | SDA-2026-04-03-26abc5e5f9f2 |
| sess_gap-methodol-20 | Methodology challenge: notebook 'Astrocyte reactivity subtypes in neurodegenerat | 0.50 | 0 | 2 | scheduled | 2026-04-27 | |
| sess_gap-methodol-20 | Methodology challenge: notebook 'Blood-brain barrier transport mechanisms for an | 0.50 | 0 | 3 | scheduled | 2026-04-27 | |
| sess_gap-methodol-20 | Methodology challenge: notebook 'Mitochondrial transfer between neurons and glia | 0.50 | 0 | 2 | scheduled | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_b13ee4ef | test debate from CLI | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| pan_9e2d5a81 | are cell types real? | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| test-chamber-session | test question | 0.50 | 0 | 0 | completed | 2026-04-27 | |
| sess_hypdeb_h_de0d43 | Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy | 0.40 | 1 | 4 | completed | 2026-04-27 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| sess_hypdeb_h_58e463 | Hypothesis debate: SASP-Mediated Complement Cascade Amplification | 0.40 | 1 | 4 | completed | 2026-04-27 | sda-2026-04-01-gap-013 |
| sess_hypdeb_h_260048 | Hypothesis debate: CYP46A1 Overexpression Gene Therapy | 0.40 | 1 | 4 | completed | 2026-04-27 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| sess_SDA-2026-04-26- | Investigate how microglial senescence drives ALS progression through inflammatio | 0.50 | 3 | 4 | completed | 2026-04-27 | SDA-2026-04-26-gap-20260425215446 |
| sess_SDA-2026-04-26- | What is the evidence that blood-brain barrier (BBB) permeability changes serve a | 1.00 | 3 | 4 | completed | 2026-04-27 | SDA-2026-04-26-gap-bbb-permeability-biomarker-20260426 |
| target_debate_target | Should SYNTHETICFUSIONPROTEINS (SYNTHETICFUSIONPROTEINS) be prioritized as a the | 0.28 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should LAMP2B (LAMP2B) be prioritized as a therapeutic target for neurodegenerat | 0.33 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DISEASE-CAUSINGMUTATIONSWITHINTEGRATEDREPORTERS (DISEASE-CAUSINGMUTATIONS | 0.31 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PITX3 (PITX3) be prioritized as a therapeutic target for neurodegeneratio | 0.33 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PGC1A (PGC1A Protein) be prioritized as a therapeutic target for neurodeg | 0.37 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should SLC16A1 (Monocarboxylate transporter 1 (MCT1)) be prioritized as a therap | 0.42 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should AGER (AGER Protein) be prioritized as a therapeutic target for neurodegen | 0.38 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should MITOCHONDRIALBIOGENESISGENES (MITOCHONDRIALBIOGENESISGENES) be prioritize | 0.40 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should TDC (TDC Protein) be prioritized as a therapeutic target for neurodegener | 0.38 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should SPTLC1 (SPTLC1 Protein) be prioritized as a therapeutic target for neurod | 0.37 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should NURR1 (NURR1 Protein) be prioritized as a therapeutic target for neurodeg | 0.38 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should CELL-TYPE-SPECIFIC (CELL-TYPE-SPECIFIC Protein) be prioritized as a thera | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should SYNTHETIC (SYNTHETIC Protein) be prioritized as a therapeutic target for | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should SLC17A7 (Vesicular glutamate transporter 1 (VGLUT1)) be prioritized as a | 0.48 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DISEASE-CAUSING (DISEASE-CAUSING Protein) be prioritized as a therapeutic | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DNAJB6 (DNAJB6 Protein) be prioritized as a therapeutic target for neurod | 0.39 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should ACSL4 (Long-chain-fatty-acid--CoA ligase 4) be prioritized as a therapeut | 0.49 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PVALB (Parvalbumin) be prioritized as a therapeutic target for neurodegen | 0.33 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PHB2 (PHB2 Protein) be prioritized as a therapeutic target for neurodegen | 0.41 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should TFEB (TFEB Protein) be prioritized as a therapeutic target for neurodegen | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should RHOT1 (RHOT1 Protein) be prioritized as a therapeutic target for neurodeg | 0.40 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should C4B (C4B Protein) be prioritized as a therapeutic target for neurodegener | 0.44 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DGAT1ANDSOAT1 (DGAT1ANDSOAT1) be prioritized as a therapeutic target for | 0.47 | 0 | 4 | completed | 2026-04-27 | |